Paper Details

  1. Home
  2. Paper Details

Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial.

Author: FioreStefano, FleischmannRoy M, GenoveseMark C, HuangXiaohong, HuizingaTom W J, JassonMartine, RadinAllen R, StahlNeil, YancopoulosGeorge D, van AdelsbergJanet

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This dose-ranging study evaluated the safety and efficacy of weekly and every-other-week dosing of sarilumab, an anti-interleukin 6 receptor α (anti-IL-6Rα) monoclonal antibody, for moderate-to-severe rheumatoid arthritis (RA). The study found that sarilumab improved signs and symptoms of RA with a safety profile similar to other IL-6 inhibitors. Dosing of 150 mg and 200 mg every other week appeared to have the most favorable efficacy, safety, and dosing convenience.
Paper Details　
Original Abstract of the Article :
OBJECTIVES: To evaluate safety and efficacy of weekly (qw) and every other week (q2w) dosing of sarilumab, a fully human anti-interleukin 6 receptor α (anti-IL-6Rα) monoclonal antibody, for moderate-to-severe rheumatoid arthritis (RA). METHODS: In this dose-ranging study, patients (n=306) with acti...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4145418/

データ提供：米国国立医学図書館（NLM）

Crossing the Desert of Rheumatoid Arthritis: Exploring Sarilumab as a Treatment Option

Rheumatoid arthritis, a chronic inflammatory disease that affects the joints, can be a debilitating condition that feels like navigating a relentless desert of pain and stiffness. This study investigates the potential of sarilumab, a fully human monoclonal antibody targeting the IL-6 receptor, as a treatment for rheumatoid arthritis. Researchers conducted a dose-ranging study in patients with moderate-to-severe rheumatoid arthritis who had an inadequate response to methotrexate. They found that sarilumab significantly improved signs and symptoms of rheumatoid arthritis, leading to a reduction in disease activity and improved quality of life. The study highlights the potential of sarilumab as a promising treatment option for rheumatoid arthritis, offering a glimmer of hope for those struggling with this challenging condition.

A New Oasis for Rheumatoid Arthritis: Exploring the Potential of Sarilumab

This study explores the potential of sarilumab, a fully human monoclonal antibody targeting the IL-6 receptor, as a treatment for rheumatoid arthritis. Researchers found that sarilumab significantly improved signs and symptoms of the disease, leading to a reduction in disease activity and improved quality of life. The study highlights the promise of sarilumab as a potential treatment option for rheumatoid arthritis, offering a glimmer of hope for those seeking relief from this challenging condition.

Finding Relief in the Desert: Managing Rheumatoid Arthritis

The study underscores the importance of seeking appropriate treatment options for rheumatoid arthritis. The research highlights the potential of sarilumab, a fully human monoclonal antibody targeting the IL-6 receptor, as a promising treatment for this condition. Open communication with your healthcare provider about potential treatment options and ongoing research in this area is crucial for navigating the challenging landscape of rheumatoid arthritis.

Dr. Camel's Conclusion

This study provides a glimmer of hope for those struggling with rheumatoid arthritis, highlighting the potential of sarilumab as a promising treatment option. The research suggests that sarilumab can significantly improve signs and symptoms of the disease, offering a path towards a more comfortable and fulfilling life. It underscores the importance of seeking appropriate treatment options and staying informed about ongoing research in this area.

Date :
  1. Date Completed 2014-10-16
  2. Date Revised 2022-04-09
Further Info :

Pubmed ID

24297381

DOI: Digital Object Identifier

PMC4145418

Related Literature

Article Analysis
・Effects of sarilumab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.